Neovacs Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 11

Employees

  • Stock Symbol
  • ALNEV

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $0.05
  • (As of Friday Closing)

Neovacs General Information

Description

Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Contact Information

Website
www.neovacs.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 14 rue de la republique
  • 92150 Suresnes
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Vertical(s)
Corporate Office
  • 14 rue de la republique
  • 92150 Suresnes
  • France
+33 01

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neovacs Stock Performance

As of 20-Nov-2026, Neovacs’s stock price is $0.05. Its current market cap is $8.05K with 160K shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.05 $0.05 $0.04 - $310.84 $8.05K 160K 136K -$61.1K

Neovacs Financials Summary

As of 30-Jun-2026, Neovacs has a trailing 12-month revenue of $327K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 161 165
Revenue 327 365 396 578
EBITDA (6,014) (5,819) (30,368) (6,556)
Net Income (4,772) (5,524) (35,617) (9,461)
Total Assets 25,351 26,040 22,966 58,102
Total Debt 805 631 240 719
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Neovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Neovacs‘s full profile, request access.

Request a free trial

Neovacs Patents

Neovacs Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022330351-A1 Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof Pending 20-Aug-2021
CA-3229324-A1 Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof Pending 20-Aug-2021
EP-4387648-A1 Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof Pending 20-Aug-2021
US-20250312427-A1 Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof Pending 20-Aug-2021
WO-2023021195-A1 Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof Inactive 20-Aug-2021 A61K39/0008
To view Neovacs’s complete patent history, request access »

Neovacs Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neovacs Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Neovacs‘s full profile, request access.

Request a free trial

Neovacs Investments (6)

Neovacs’s most recent deal was a Early Stage VC with NETRI for . The deal was made on 26-Apr-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NETRI 26-Apr-2022 Early Stage VC Medical Supplies
Signia Therapeutics 20-Nov-2021 Early Stage VC Drug Discovery
Joint Venture (Neovacs / Priority One Canine) 30-Sep-2021 Joint Venture Other Healthcare Services
The Famar Factory 29-Jun-2020 Corporate Buildings and Property
AMEGABiotech (Interferon Alpha Manufacturing Technology) 15-Nov-2016 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 6 investments. Get the full list »

Neovacs ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Neovacs’s complete esg history, request access »

Neovacs Exits (2)

Neovacs’s most recent exit was on 20-Nov-2021 from Signia Therapeutics. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Signia Therapeutics 20-Nov-2021 Completed
  • 2 buyers
The Famar Factory 29-Jun-2020 Corporate Completed
To view Neovacs’s complete exits history, request access »

Neovacs FAQs

  • When was Neovacs founded?

    Neovacs was founded in 1993.

  • Where is Neovacs headquartered?

    Neovacs is headquartered in Suresnes, France.

  • What is the size of Neovacs?

    Neovacs has 11 total employees.

  • What industry is Neovacs in?

    Neovacs’s primary industry is Drug Discovery.

  • Is Neovacs a private or public company?

    Neovacs is a Public company.

  • What is Neovacs’s stock symbol?

    The ticker symbol for Neovacs is ALNEV.

  • What is the current stock price of Neovacs?

    As of 20-Nov-2026 the stock price of Neovacs is $0.05.

  • What is the current market cap of Neovacs?

    The current market capitalization of Neovacs is $8.05K.

  • What is Neovacs’s current revenue?

    The trailing twelve month revenue for Neovacs is $327K.

  • What is Neovacs’s annual earnings per share (EPS)?

    Neovacs’s EPS for 12 months was -$61.1K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process